<DOC>
	<DOCNO>NCT02759237</DOCNO>
	<brief_summary>The Medtronic Transcatheter Aortic Valve Implant System ( CoreValve System Family ) demonstrate safe effective high extreme risk patient symptomatic severe native aortic stenosis stenosed , insufficient , combine surgical bioprosthetic valve failure . Per DCGI systematic post marketing surveillance requirement , purpose PMS plan provide local post marketing surveillance data regard safety Medtronic CoreValve System Family</brief_summary>
	<brief_title>The Medtronic Transcatheter Aortic Valve Implant System ( CoreValve System Family ) Post Marketing Surveillance ( PMS ) ( CoreValve India PMS )</brief_title>
	<detailed_description>The objective PMS monitor gather data safety The Medtronic Transcatheter Aortic Valve Implant System ( CoreValve System Family ) approve intend use . The main focus PMS generate additional information report major adverse event 30 day day implant procedure .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Patients symptomatic heart disease due severe native calcific aortic stenosis stenosed , insufficient , combine surgical bioprosthetic valve failure anatomy appropriate 23 , 26 , 29 31 mm valve system judge heart team , include cardiac surgeon , high great risk open surgical therapy . Indications contraindication provide product Instructions Use . Subject schedule receive transcatheter aortic valve Subject 18 year age older The patient his/her Legally Authorized Representative ( LAR ) inform nature PMS Informed consent Audio Visual ( AV ) record study participation obtain prior perform studyrelated procedure subject Legally Authorized Representative , per applicable local requirement India</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>